Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

被引：0
|
作者：
Dhanashree Ratra
Krishnakanta Roy
Sneha Giridhar
Sushant Madaan
机构：
[1] Medical Research Foundation,Department of Vitreoretinal Diseases
[2] Sankara Nethralaya,undefined
来源：
Ophthalmology and Therapy | 2022年 / 11卷
关键词：
Anti VEGF; Biosimilar; Comparison with bevacizumab; DME; nAMD; Ranibizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：135 / 149
页数：14
相关论文
共 50 条
  • [41] Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
    Ashish Sharma
    Nilesh Kumar
    Nikulaa Parachuri
    Francesco Bandello
    Baruch D. Kuppermann
    Anat Loewenstein
    Eye, 2022, 36 : 1106 - 1107
  • [42] Real-world utilization of ranibizumab in wetage related macular degeneration patients from Canada
    Devenyi, Robert
    Maberley, David
    Sheidow, Tom G.
    Tourville, Eric
    Brunck, Lynne
    Berger, Alan R.
    CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE, 2016, 51 (02): : 55 - 57
  • [43] Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity A Multicenter Study
    Patel, Nimesh A.
    Acaba-Berrocal, Luis A.
    Hoyek, Sandra
    Fan, Kenneth C.
    Martinez-Castellanos, Maria Ana
    Baumal, Caroline R.
    Harper, C. Armitage, III
    Berrocal, Audina M.
    OPHTHALMOLOGY, 2023, 130 (04) : 373 - 378
  • [44] AGE RELATED MACULAR DEGENERATION Cost comparison of ranibizumab and bevacizumab
    Jackson, Timothy L.
    Kirkpatrick, Lucy
    BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [45] Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series
    Gangwe, Anil Babanrao
    Ekumankama, Chibuzo B.
    Singh, Abhishek
    Parchand, Swapnil Madhukar
    Agrawal, Deepshikha
    Azad, Raj Vardhan
    INDIAN JOURNAL OF OPHTHALMOLOGY, 2025, 73 (SUPPL 1)
  • [46] Safety Profile Comparison Between Topical Pegaptanib (Macugen®), Bevacizumab (Avastin®) and Ranibizumab (Lucentis®)
    Bucher, F.
    Bock, F.
    Hos, D.
    Cursiefen, C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2010, 51 (13)
  • [47] Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
    Chang, Yi-Sheng
    Lee, Wan-Ju
    Lim, Chen-Chee
    Wang, Shih-Hao
    Hsu, Sheng-Min
    Chen, Yi-Chian
    Cheng, Chia-Yi
    Teng, Yu-Ti
    Huang, Yi-Hsun
    Lai, Chun-Chieh
    Tseng, Sung-Huei
    SCIENTIFIC REPORTS, 2018, 8
  • [48] Real-world outcomes of ranibizumab treatment in patients with retinal vein occlusion: the LUMINOUS™ study
    Pearce, Ian A.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [49] Comparison of Intravitreal Bevacizumab and Ranibizumab Treatment for Diabetic Macular Edema
    Ozturk, Banu Turgut
    Kerimoglu, Hurkan
    Bozkurt, Banu
    Okudan, Suleyman
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 27 (04) : 373 - 377
  • [50] Real-world outcomes of ranibizumab in patients with retinal vein occlusion from the LUMINOUS™ study
    Pearce, Ian
    Parikh, Soumil
    Macfadden, Wayne
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
12345